First research action for Medical counter measures performed in the frame of the RESILIENCE FPA consortium

Project “First research action for Medical counter measures performed in the frame of the RESILIENCE FPA consortium” (RESILIENCE-R-2023) aims to develop and test novel medical countermeasures (MCMs) against CBRNs in the framework of the three pillars of the RESILIENCE FPA multiannual action plan - Diagnosis, Prevention & Prophylaxis and Treatments, with the following specific objectives:
• OB1) Design early and high-throughput diagnosis (point of care as well as reach-back capabilities) of acute and late radiation-induced human health effects in preparedness of RN event
• OB2) Design of innovative decorporating and human decontaminating agents for NR threats
• OB3) Elaborate phage-based diagnostics and therapeutics for infections caused by CBRN relevant bacteria
• OB4) Design new generation vaccines against Monkeypox virus (MPXV) and Variola virus (VARV)
• OB5) Design next generation of re-activators of cholinesterases against nerve agent intoxication.
Current lab-scale MCMs will be brought to TRL4/5 through further optimisation and testing. A panel of complementary activities will be undertaken, including knowledge generation (new biomarkers of late radiation induced effects, new concepts of vaccines), knowledge integration (new vaccines, phage therapies and decorporating agents, new in vitro diagnostic tools for rapid and on-field identification of microorganisms, evaluation of new reactivators of cholinesterases against nerve agent intoxication), and studies (in vitro and in vivo assays for preclinical proof of concept studies of MCM candidates, characterisation of drugs and devices for further formulation and vectorisation).